After weathering failure, rejection and layoffs, ImmunoGen touts a new 'breakthrough' drug in its comeback plan
While the comeback plan for its lead drug is still up in the air, ImmunoGen says it has a second shot at an antibody-drug conjugate …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.